Ustekinumab biosimilar - Oncobiologics

Drug Profile

Ustekinumab biosimilar - Oncobiologics

Alternative Names: ONS-3040

Latest Information Update: 20 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncobiologics
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Psoriasis

Most Recent Events

  • 14 Feb 2018 Preclinical development is ongoing in USA (Oncobiologics pipeline, February 2018)
  • 14 Feb 2018 Oncobiologics plans a clinical trial for ONS 3040 in 2020
  • 22 Oct 2015 Preclinical trials in Psoriasis in USA (SC) prior to October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top